Dr. Robert Hariri resigned as Director at BIOVIE INC..
“On March 28, 2025, Dr. Robert Hariri informed BioVie Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective as of such date.”
Source-grounded facts extracted from BIOVIE INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Dr. Robert Hariri resigned as Director at BIOVIE INC..
“On March 28, 2025, Dr. Robert Hariri informed BioVie Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective as of such date.”
Steve Gorlin resigned as Director at BIOVIE INC..
“On July 25, 2024, Steve Gorlin notified the Board of Directors (the “Board”) of BioVie Inc. (the “Company”) of his intention to resign as a director of the Company, effective immediately.”
BIOVIE INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“April 18, 2024, BioVie Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180 calendar day grace period, or until October 15, 2024, to regain compliance with the minimum bid price requirement. The continued listing standard will”
BIOVIE INC. entered into Agreement with ThinkEquity LLC valued at approximately $21,000,000 million (effective 2024-03-04).
“On March 4, 2024, BioVie Inc. (the “ Company ”) entered into a placement agent agreement (the “ Agreement ”) with ThinkEquity LLC, as the placement agent (the “ Placement Agent ”), in connection with the issuance and sale (the “ Offering ”) directly to various investors (the “ Investors ”) of up to 21,000,000 shares”
BIOVIE INC. shareholders approved Approval and Ratification of Auditors at the 2023-11-08 meeting.
“Stockholders approved and ratified the appointment of EisnerAmper LLP to serve as the Company’s independent registered public accounting firm for the 2024 fiscal year. The voting results were as follows: For Against Abstain Broker Non-Vote 29,275,023 180,567 19,155 4,528,595”
BIOVIE INC. shareholders approved Election of Directors at the 2023-11-08 meeting.
“Stockholders elected all of the Company’s nominees for director for one-year terms expiring at the next annual meeting of stockholders upon election and qualification of their successors. The voting results were as follows: For Withhold Broker Non-Vote (1) CUONG DO 24,871,797 74,353 4,528,595 (2) JIM LANG 24,557,658 388,492 4,528,595 (3) MICHAEL SHERMAN 24,630,002 316,148 4,528,595 (4) RICHARD J. BERMAN 24,526,699 419,451 4,528,595 (5) STEVE GORLIN 24,602,592 343,558 4,528,595 (6) ROBERT HARIRI, M.D. PHD 24,774,046 172,104 4,528,595 (7) SIGMUND ROGICH 24,867,955 78,195 4,528,595”
BIOVIE INC.: Adopted First Amendment to Bylaws granting Chairman and CEO authority to call special Board meetings with four hours notice and reducing required board size range from nine fixed to three to eleven (effective 2023-03-12).
“On March 12, 2023, the board of directors of BioVie Inc. (the “Company”) approved and adopted the first amendment (the “First Amendment”) to the amended and restated bylaws of the Company (the “Bylaws”), which became effective immediately. The First Amendment amends the Bylaws to (i) provide each of the Chairman of the Board and the Chief Executive Officer with the authority to call a special meeting of the Board with no less than four hours prior notice and (ii) reduce the required number of directors on the Board from nine directors to no less than three nor more than eleven.”
Jim Lang was elected as Chairman of the Board at BIOVIE INC..
“The Board has elected Jim Lang, a current director of the Company, to serve as the new Chairman of the Board, effectively immediately.”
Terren S. Peizer resigned as Chairman of the Board at BIOVIE INC..
“On March 2, 2023, BioVie Inc. (the “Company”) accepted the resignation of Terren S. Peizer, Chairman of the Board of Directors of the Company (the “Board”), effective immediately”
BIOVIE INC. shareholders approved Approval and Ratification of Auditors at the 2022-11-09 meeting.
“Stockholders approved and ratified the appointment of EisnerAmper LLP to serve as the Company’s independent registered public accounting firm for the 2023 fiscal year. The voting results were as follows: For Against Abstain Broker Non-Vote 25,617,605 94,990 12,546 1,760,515”
BIOVIE INC. shareholders approved Election of Directors at the 2022-11-09 meeting.
“Stockholders elected all of the Company’s nominees for director for one-year terms expiring at the next annual meeting of stockholders upon election and qualification of their successors. The voting results were as follows: For Withhold Broker Non-Vote (1) TERREN S. PEIZER 23,780,558 184,068 1,760,515 (2) CUONG DO 23,916,874 37,752 1,760,515 (3) JIM LANG 23,889,937 74,689 1,760,515 (4) MICHAEL SHERMAN 23,917,129 37,497 1,760,515 (5) RICHARD J. BERMAN 23,832,311 132,315 1,760,515 (6) STEVE GORLIN 23,917,129 37,501 1,760,515 (7) ROBERT HARIRI, M.D. PHD 23,878,804 85,822 1,760,515 (8) SIGMUND ROGICH 23,923,084 41,542 1,760,515”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.